StreetInsider.com News Articles

Raymond James reiterates strong buy on Palvella Therapeutics (PVLA)

Fri, 16 Oct 2026 09:22:52 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $226.00 price target on Palvella Therapeutics (NASDAQ: PVLA).

The reiteration follows Palvella's presentation of two posters at the 2026 Pediatric Dermatology Research Alliance Annual Conference, held October 15-17, 2026. The posters featured pediatric subgroup analyses from the Phase 3 SELVA and Phase 2 TOIVA clinical studies.

The SELVA analysis examined patients aged 6-11 and 12-17, reporting reductions in lesion height, leaking/bleeding, and vesicle appearance following 168 days of treatment with QTORIN rapamycin. The TOIVA pediatric analysis reported improvements in lesion severity and bleeding through Week 24, along with high treatment satisfaction.

Deschner

William Blair Starts Palvella Therapeutics (PVLA) at Outperform

Fri, 16 Oct 2026 03:10:18 -0400

William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Outperform rating.

The analyst comments: “We are initiating coverage of Palvella with an Outperform rating and DCF valuation of $266 per share. Palvella is a rare disease company that takes drugs already known to work and reformulates them with its QTORIN platform into topical gels that get the drug deep into the skin. Its lead product, QTORIN rapamycin, had positive Phase III data in microcystic lymphatic malformations (mLMs) earlier this year. This will be the company’s first approval, so we are reaching an important transition for the

William Blair Starts Palvella Therapeutics (PVLA) at Outperform

Fri, 16 Oct 2026 03:10:18 -0400

William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Outperform rating.

Palvella to present trial data at pediatric dermatology conference

Thu, 15 Oct 2026 07:31:03 -0400

Palvella Therapeutics (Nasdaq: PVLA) announced it will present two posters at the Pediatric Dermatology Research Alliance Annual Conference, taking place Oct. 15–17, 2026, in Alexandria, Virginia.

The presentations will feature previously reported results from the company's Phase 3 SELVA and Phase 2 TOIVA clinical studies of its investigational product QTORIN rapamycin, along with new pediatric analyses. Both posters are scheduled for a poster reception on Oct. 15, 2026, from 5:00 to 7:00 p.m., and will be presented by Kristen Kahle, Ph.D.

The Phase 3 SELVA pediatric analyses cover improvements in overall disease severity and a blinded combined score of lesion height, vesicle

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Thu, 15 Oct 2026 07:30:00 -0400

Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding

Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations

QTORIN™ Rapamycin Has the Potential to Become the First FDA-Approved Therapy for Both Microcystic Lymphatic Malformations and Cutaneous Venous Malformations, Two Serious, Rare Diseases with No FDA-Approved Therapies

WAYNE, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq:

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Thu, 15 Oct 2026 07:30:00 -0400

Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding

Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations

WAYNE, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq:

Form 4 PALVELLA THERAPEUTICS, For: Oct 12 Filed by: JENKINS GEORGE M

Wed, 14 Oct 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20261014/27188155.html

Form 144 PALVELLA THERAPEUTICS, Filed by: JENKINS GEORGE M

Tue, 13 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261013/27181799.html

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Tue, 13 Oct 2026 07:30:00 -0400

WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 1:45 p.m. ET.

A live webcast of the fireside chat will be available on the Events and

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Tue, 13 Oct 2026 07:30:00 -0400

A live webcast of the fireside chat will be available on the Events and

Palvella presents clinical and claims data at dermatology conference

Mon, 12 Oct 2026 07:30:45 -0400

Palvella Therapeutics (Nasdaq: PVLA) presented three posters at the 26th Annual Fall Clinical Dermatology Conference on Oct. 12, 2026, sharing data from its Phase 3 SELVA study and a real-world claims analysis.

In the SELVA qualitative interview study, all exit-interview participants at Week 24 reported improvement in at least one symptom of microcystic lymphatic malformations (microcystic LMs), with bleeding/leaking and color cited most commonly. All participants who completed the treatment satisfaction questionnaire reported satisfaction, and 98% of those who completed the 24-week Efficacy Evaluation Period elected to continue into the Treatment Extension Period. Among completers, 95% showed improvement on the primary

Palvella presents clinical and claims data at dermatology conference

Mon, 12 Oct 2026 07:30:45 -0400

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026

Mon, 12 Oct 2026 07:30:00 -0400

Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin

SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours

Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S.

WAYNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026

Mon, 12 Oct 2026 07:30:00 -0400

Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin

SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours

Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S.

Palvella Therapeutics (PVLA) PT Lowered to $246 at H.C. Wainwright

Mon, 12 Oct 2026 06:50:53 -0400

H.C. Wainwright analyst Andrew Fein lowered the price target on Palvella Therapeutics (NASDAQ: PVLA) to $246.00 (from $270.00) while maintaining a Buy rating.

FDA awards Palvella third year of orphan products grant funding

Mon, 28 Sep 2026 07:32:15 -0400

Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received a third year of grant funding from the FDA Office of Orphan Products Development for its QTORIN rapamycin program, targeting microcystic lymphatic malformations.

The funding supports the Phase 3 SELVA trial and an ongoing open-label extension study of QTORIN 3.9% rapamycin anhydrous gel. The FDA awarded the grant following its review of Palvella's annual performance progress report, which included results from the Phase 3 SELVA trial.

In February 2026, Palvella reported positive topline results from the Phase 3 SELVA trial, stating that the study met its primary endpoint, a pre-specified key secondary endpoint,

FDA awards Palvella third year of orphan products grant funding

Mon, 28 Sep 2026 07:32:15 -0400

In February 2026, Palvella reported positive topline results from the Phase 3 SELVA trial, stating that the study met its primary endpoint, a pre-specified key secondary endpoint,

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Mon, 28 Sep 2026 07:30:00 -0400

NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved

QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.

WAYNE, Pa., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Mon, 28 Sep 2026 07:30:00 -0400

NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved

Chardan Assumes Palvella Therapeutics (PVLA) at Buy

Mon, 21 Sep 2026 06:04:19 -0400

Chardan analyst Gautam Chukka assumes coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Buy rating and a price target of $240.00.

For an analyst ratings summary and ratings history on Palvella Therapeutics click here. For more ratings news on Palvella Therapeutics click here.

Shares of Palvella Therapeutics closed at $150.56 yesterday.

Form 4 PALVELLA THERAPEUTICS, For: Sep 16 Filed by: Goin Kathleen

Fri, 18 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260918/27080529.html

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) said its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged life sciences advisory firm Red Sky Partners and independent advisor Martin Hendrix, Ph.D., to support the development of its investigational drug candidate NB4168 and broader corporate strategy.

Red Sky Partners advisors Pauline Jen Ryan and Christopher Kiritsy will focus on drug development, fundraising, strategic transactions, and commercialization. Ryan has nearly four decades of experience advising biotechnology companies and previously served as Senior Vice President of Corporate Development at ImmunoGen, where she helped raise close to $300 million. Kiritsy played a central role in building Kos Pharmaceuticals,

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

Advisors bring biotechnology fundraising, drug development, and commercialization, as well as corporate strategy and M&A expertise to support the advancement of NB4168 and strategic corporate growth initiatives

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400